HATS off to KAT6A/B inhibitors: A new way to target estrogen-receptor-positive breast cancer
{{output}}
Inhibitors for the KAT6 family of histone acetyltransferases (HATs) have been actively pursued due to the oncogenic roles of KAT6A in human cancer. CTx-648 is a novel KAT6A/B inhibitor with excellent pharmacokinetic properties and in vivo efficacy that represe... ...
